Multiple sulfatase deficiency (MSD) is an extremely rare autosomal recessive hereditary disorder caused by pathogenic variants in the SUMF1 gene. The alteration of this gene prevents the proper activation of multiple sulfatases, leading to lysosomal accumulation of glycosaminoglycans, sulfolipids, and other sulfated substrates. The disease progressively affects the nervous system, skeleton, skin, and other organs, with neonatal, infantile, and juvenile forms depending on the age of onset and clinical severity.
Multiple sulfatase deficiency
The SUMF1 gene encodes the formylglycine-generating enzyme (FGE), which is required to activate sulfatases via an essential post-translational modification at their catalytic site. Sulfatases are enzymes responsible for degrading molecules with sulfate groups, mainly glycosaminoglycans (GAGs), sulfolipids, and other sulfated compounds.
When SUMF1 presents pathogenic variants, FGE activity decreases or disappears and sulfatases remain partially or completely inactive. As a consequence, sulfated substrates accumulate in lysosomes and clinical features of mucopolysaccharidosis, metachromatic leukodystrophy, X-linked ichthyosis, and chondrodysplasia punctata are combined. MSD is inherited in an autosomal recessive manner: the affected person has usually inherited two pathogenic variants, one from each parent. It is an ultra-rare disease, with an estimated prevalence close to 1 in 1.4 million people and cases described in different ethnic groups.
Symptoms
The clinical picture is variable and depends on the residual FGE activity. Neonatal forms are the most severe, with dysmorphic features, hypotonia, feeding problems, skeletal anomalies, ichthyosis, and early neurological involvement. In infantile forms, which are the most frequent, developmental delay or regression, progressive loss of motor and intellectual skills, spasticity, seizures, coarse facies, multiple dysostosis, hepatosplenomegaly, and skin alterations usually appear. Juvenile forms may debut later and progress more slowly, although they can also evolve with neurological and orthopedic deterioration.
Disease management
Currently, there is no approved curative therapy or enzyme replacement therapy for MPS. Management is supportive and should be multidisciplinary, with neurological, metabolic, orthopedic, dermatological, respiratory, and nutritional follow-up according to each patient's manifestations. It may include physical and occupational therapy, seizure treatment, feeding and swallowing support, respiratory infection control, and management of orthopedic complications. Anticipatory surveillance for complications and family genetic counseling are essential. Strategies such as gene therapy and approaches aimed at restoring FGE function are being investigated, but do not yet constitute standard treatment.
Genes analyzed
Bibliography
Cosma MP, Pepe S, Parenti G, et al. Molecular and functional analysis of SUMF1 mutations in multiple sulfatase deficiency. Hum Mutat. 2004 Jun;23(6):576-81.
Sabourdy F, Mourey L, Le Trionnaire E, et al. Natural disease history and characterisation of SUMF1 molecular defects in ten unrelated patients with multiple sulfatase deficiency. Orphanet J Rare Dis. 2015 Mar 15;10:31.
Ahrens-Nicklas R, Schlotawa L, Ballabio A, et al. Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement. Mol Genet Metab. 2018 Mar;123(3):337-346.
